Antikor Biopharma

Antibody Drug Conjugates (ADCs) are now a well established, clinically and commercially proven form of antibody therapeutics allowing the specific tumour delivery of potent cytoxic payloads. After many years, we are seeing many product approvals with the likes of Enhertu and Tivdak driving confidence and momentum. However, despite their success, whole monoclonal antibody (MAb)-based ADCs have intrinsic failings which limit their efficacy in solid tumours, causes unacceptable dose-limiting sid...